The presentation of promising preclinical and interim clinical data at a major congress can positively influence investor sentiment. The superior performance of the AAV1 vector in achieving higher human progranulin levels and improving lysosomal histopathology suggests potential for future success, likely leading to a positive short-term impact on Passage Bio's stock price.